Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
McKesson
Chinese Patent Office
McKinsey
UBS
Express Scripts
QuintilesIMS
Queensland Health
Accenture
Mallinckrodt

Generated: February 23, 2018

DrugPatentWatch Database Preview

TAGAMET Drug Profile

« Back to Dashboard

Which patents cover Tagamet, and when can generic versions of Tagamet launch?

Tagamet is a drug marketed by Glaxosmithkline and Medtech Products and is included in six NDAs.

The generic ingredient in TAGAMET is cimetidine. There are twenty-five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the cimetidine profile page.

US Patents and Regulatory Information for TAGAMET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline TAGAMET cimetidine hydrochloride INJECTABLE;INJECTION 017939-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medtech Products TAGAMET HB cimetidine TABLET;ORAL 020238-001 Jun 19, 1995 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Medtech Products TAGAMET HB cimetidine TABLET;ORAL 020238-002 Aug 21, 1996 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine hydrochloride SOLUTION;ORAL 017924-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-005 Apr 30, 1986 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-004 Dec 14, 1983 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER cimetidine hydrochloride INJECTABLE;INJECTION 019434-001 Oct 31, 1985 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET HB 200 cimetidine SUSPENSION;ORAL 020951-001 Jul 9, 1999 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for TAGAMET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline TAGAMET cimetidine hydrochloride INJECTABLE;INJECTION 017939-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine hydrochloride SOLUTION;ORAL 017924-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-004 Dec 14, 1983 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-003 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-004 Dec 14, 1983 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-003 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine hydrochloride INJECTABLE;INJECTION 017939-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TAGAMET cimetidine TABLET;ORAL 017920-005 Apr 30, 1986 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Johnson and Johnson
Cerilliant
Accenture
Teva
Boehringer Ingelheim
QuintilesIMS
Federal Trade Commission
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot